Task Force to Evaluate Vitamins, Pharmacologics as Cancer Prophylaxis

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 8 No 5
Volume 8
Issue 5

ROCKVILLE, Md-Two cancer-related topics are among four new evaluations the Agency for Health Care Policy and Research (AHCPR) has asked the U.S. Preventive Services Task Force to make. The task force is an independent panel of preventive health experts that evaluates the effectiveness of a wide range of clinical preventive services.

ROCKVILLE, Md—Two cancer-related topics are among four new evaluations the Agency for Health Care Policy and Research (AHCPR) has asked the U.S. Preventive Services Task Force to make. The task force is an independent panel of preventive health experts that evaluates the effectiveness of a wide range of clinical preventive services.

The AHCPR has asked that the group address chemoprophylaxis for breast cancer, including use of tamoxifen (Nolvadex) and related drugs, and to evaluate vitamin supplementation as a means of preventing cancer and heart disease. The Agency also asked the panel to assess screening for bacterial vaginosis in pregnancy and developmental screening in children.

Among the eight previously studied topics for which AHCPR wants new evaluations are skin cancer screening and postmenopausal hormone therapy.

Articles in this issue
Delirium Is Often Misdiagnosed in Advanced Cancer
Preop Chemo Recommended for Locally Advanced Disease
High Degree of Variability in HIV Testing Throughout the US
Physicians Need ‘Coherent Game Plan’ for Care of Dying
NCI Funds Pediatric Brain Tumor Consortium
Marketing Your Cancer Center to Today’s Savvy Consumers
Axillary Irradiation Can Replace Dissection in Some Breast Cancer’s
Dr. Bailes Urges Oncologists to Act Against APC Proposal
Elective Lymph Node Dissection Supported in Some Melanomas
Broad Coalition of Health Care Groups Opposes APCs
Depression and Anxiety Difficult to Diagnose in Cancer Patients
Tips on Distinguishing Good Metaanalyses From Poor Ones
How Patients Hear a Cancer Diagnosis Can Affect Long-Term QOL
Neoadjuvant Hormonal Therapy in Prostate Cancer: Pro and Con
Treating Patients on Protocol More Effective, No More Costly

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
4 experts in this video
2 experts in this video
2 experts in this video
4 experts in this video
A study aimed to determine the variables that correlated with extravasation rates in patients receiving radiation injection therapy.
Related Content
Univariate and multivariate analyses showed no significant association between statin use and grade 3 or higher toxicities in patients with CLL or SLL.

Concurrent Statin Use With Treatment Improves Survival in CLL/SLL

Roman Fabbricatore
April 25th 2025
Article

Univariate and multivariate analyses showed no significant association between statin use and grade 3 or higher toxicities in patients with CLL or SLL.

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS
April 21st 2025
Podcast

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

CHMP Recommends Brentuximab Vedotin/Chemo in Advanced Hodgkin Lymphoma

CHMP Recommends Brentuximab Vedotin/Chemo in Advanced Hodgkin Lymphoma

Tim Cortese
April 25th 2025
Article

Results from the phase 3 HD21 trial showed that brentuximab vedotin plus chemotherapy was superior to alternative treatments in Hodgkin lymphoma.

Fostering the Future of Psychosocial Care With World Psycho-Oncology Day

Fostering the Future of Psychosocial Care With World Psycho-Oncology Day

Cristiane Decat Bergerot, PhD
April 14th 2025
Podcast

Integrating psychosocial care into cancer care allows patients to receive emotional support, counseling, and coping strategies to help navigate treatment.

Based on FDA feedback, the developers plan to discontinue the phase 3 EQUATOR study, which evaluated itolizumab in acute graft-versus-host disease.

FDA Rejects Breakthrough Designation, Approval for Itolizumab in Acute GVHD

Roman Fabbricatore
April 25th 2025
Article

Based on FDA feedback, the developers plan to discontinue the phase 3 EQUATOR study, which evaluated itolizumab in acute graft-versus-host disease.

"...The reported feasibility and activity of this combination warrant further evaluation in switch maintenance in the metastatic setting or consolidation after definite chemoradiation for patients with limited-stage SCLC," according to the study authors.

Lurbinectedin/Pembrolizumab Shows Significant Activity in Relapsed SCLC

Russ Conroy
April 25th 2025
Article

Findings from the phase 1/2 LUPER trial support further assessment of lurbinectedin plus pembrolizumab in relapsed small cell lung cancer.